PUBLICATIONS

New England Journal of Medicine


The Lancet/Lancet Oncology


British Journal of Urology


Journal of Urology


• Transurethral Photodynamic Therapy with Lemuteporfin in Men with LUTS due to BPH: Initial Clinical Experience; Perez-Marrero, Goldenberg, Shore, and Benaim; et al Journal of Urology 2005, 66 (Supplement 3A): 20.

**Urology**

• Role of Testosterone in Managing Advanced Prostate Cancer. Urology. July 2012
• Perianal Lipoma Versus Renal Cell Carcinoma. Mydello, J., Shore, N.D., Rueter, V. and Herr, H.W. Urology. (Submitted)

**Urologic Oncology**


**OTHER PUBLICATIONS:**


• Treatment of LUTS Secondary to BPH While Preserving Sexual Function: Randomized Controlled Study of Prostatic Urethral Lift. Kevin T. McVary, Steven N. Gange, Neal D. Shore et al. the Journal of Sexual Medicine. Published online SEP 30, 2013


• Chemotherapy for Prostate Cancer: When Should a Urologist Refer a Patient to a Medical Oncologist. Prostate Cancer and Prostatic Diseases advance online publication, 3 July 2012.


• Androgen Deprivation Therapy and Estrogen Deficiency Induced Adverse Effects in the Treatment of Prostate Cancer. Freedland, SJ, Eastham, J, Shore, N. Prostate Cancer and Prostatic Diseases, 1 September 2009.


• Issues with Hormone Deprivation. Shore, N.D., Debruyne, F. M.J., Crawford, E. D., Volume 8, Supplement 1, June 2009 pp. 31-41.

• Side Effects of Androgen Deprivation Therapy Induced by Estrogen Deficiency: PCRI Insights, May 2009, Neal Shore, MD and Stephen Freedland, MD.

• Targeting Prostate Cancer: An Update on the Diagnosis and Treatment of Local and Advanced Disease – Enhancing the Multidisciplinary Approach to Prostate Cancer: Improving Community Urology Involvement with Access to Clinical Trials, Neal D. Shore, MD FACS, CCRI. Medical Education Collaborative, Inc. CME Accredited, October 2007.


• The Future of LHRH Therapy; Injections and Implants: Supplement to Urology Times, June 2007.


Our Prostate Cancer Patients Need True Multidisciplinary Care; Berger and Shore; Oncology Times, Vol. XXVII, No.19. October 2005, p. 4-6.

A Multidisciplinary Approach to Managing Prostate Cancer Patients; E. Roy Berger, MD, FACP and Neal D. Shore, MD, FACS; Oncologistics, 2nd Quarter, 2005, pp. 7-10.

Early Experience with the American Medical Systems New Tactile Pump: Results of a Multicenter Study; John Delk II, MD; L. Dean Knoll, MD; James McMurray, MD; Neal D. Shore, MD; Steven Wilson, MD; Journal of Sexual Medicine, March 2005.


POSTER PUBLICATIONS:


Treatment Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (MCRPC) Patients Prior to Receiving Sipuleucel-T Data from Proceed. Neal Shore, MD et al. AUA Annual Meeting Moderated Poster Session 36, San Diego, CA. May 6, 2013.

A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.
• A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). General Poster Session, Genitourinary (Prostate) Cancer. Neal D. Shore et al. ASCO Annual Meeting May 30-June 3, 2013.

• Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials. General Poster Session, Patient and Survivor Care. Neal D. Shore et al. ASCO Annual Meeting May 30-June 3, 2013.


• A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). General Poster Session A: Prostate Cancer. Neal D. Shore et al. ASCO Annual Meeting May 30-June 3, 2013.


• Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. General Poster Session A: Prostate Cancer Oral Abstract Session A: Prostate Cancer (eQ&A). Neal D. Shore et al. ASCO Annual Meeting May 30-June 3, 2013.


• Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.


A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer. General Poster Session, Genitourinary Cancers Symposium, Orlando, FL. February 14-16, 2013.


Percutaneous Tibial Nerve Stimulation and Effect on Fecal Incontinence: Results from Two Recent Multi-Center Overactive Bladder Trials. South Central Section of the AUA, Inc. Poster. White Sulphur Springs, WV 2010.


Switching from Leuprolide to Degarelix vs. Continuous Degarelix Treatment: Effects on Long-Term Prostate-Specific Antigen Control. E David Crawford, Judd W Moul, Neal D Shore, Tine Kold Olesen, Bo-Eric Persson. AUA Poster MP20, San Francisco 2010.

Prostate-Specific Antigen and Serum Alkaline Phosphatase Levels in Prostate Cancer Patients Receiving Degarelix or Leuprolide. E David Crawford, Judd W Moul, Neal D Shore, Tine Kold Olesen, Bo-Eric Persson. AUA Poster MP28, San Francisco 2010.

Long-Term Prostate-Specific Antigen (PSA) Control in Prostate Cancer Patients Switched from Leuprolide to Degarelix or Receiving Continuous Degarelix Treatment. ASCO Poster, Chicago 2010.

Interim Results of the Spanner Prostatic Stent Post-Transurethral Microwave Thermotherapy in a Randomized Clinical Trial; Poster Presentation; Corica, Dineen, Shore, Saslawsky, Yumeman and Baum; World Congress of Endourology, 2005.

Prostate Cancer Foundation, NY, NY, November 2003; Poster Presentation: Thermal Therapy Adjuvant To Temperature Sensitive Liposomal Encapsulated Doxorubicin (Thermadox™) For The Treatment Of Prostate Cancer.